nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.111	0.275	CbGbCtD
Sirolimus—ABCB1—Lisinopril—systemic scleroderma	0.0538	0.134	CbGbCtD
Sirolimus—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0487	0.121	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—systemic scleroderma	0.0444	0.11	CbGbCtD
Sirolimus—ABCB1—Captopril—systemic scleroderma	0.0403	0.1	CbGbCtD
Sirolimus—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0317	0.0789	CbGbCtD
Sirolimus—ABCB1—Prednisone—systemic scleroderma	0.0254	0.0631	CbGbCtD
Sirolimus—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.019	0.0473	CbGbCtD
Sirolimus—CYP3A4—Prednisone—systemic scleroderma	0.0152	0.0378	CbGbCtD
Sirolimus—ABCB1—Methotrexate—systemic scleroderma	0.0127	0.0317	CbGbCtD
Sirolimus—EIF4E—connective tissue—systemic scleroderma	0.00608	0.107	CbGeAlD
Sirolimus—MTOR—blood vessel—systemic scleroderma	0.00459	0.0808	CbGeAlD
Sirolimus—EIF4E—digestive system—systemic scleroderma	0.00439	0.0774	CbGeAlD
Sirolimus—EIF4E—lung—systemic scleroderma	0.00367	0.0646	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—systemic scleroderma	0.00339	0.0598	CbGeAlD
Sirolimus—FGF2—tendon—systemic scleroderma	0.00255	0.0449	CbGeAlD
Sirolimus—MTOR—connective tissue—systemic scleroderma	0.00235	0.0414	CbGeAlD
Sirolimus—FGF2—lung—systemic scleroderma	0.00224	0.0394	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—systemic scleroderma	0.00215	0.0379	CbGeAlD
Sirolimus—MTOR—skin of body—systemic scleroderma	0.00212	0.0374	CbGeAlD
Sirolimus—FKBP1A—connective tissue—systemic scleroderma	0.00212	0.0373	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—systemic scleroderma	0.00193	0.0341	CbGeAlD
Sirolimus—FKBP1A—skin of body—systemic scleroderma	0.00191	0.0337	CbGeAlD
Sirolimus—MTOR—digestive system—systemic scleroderma	0.0017	0.0299	CbGeAlD
Sirolimus—MTOR—tendon—systemic scleroderma	0.00162	0.0285	CbGeAlD
Sirolimus—FKBP1A—digestive system—systemic scleroderma	0.00153	0.0269	CbGeAlD
Sirolimus—FKBP1A—tendon—systemic scleroderma	0.00145	0.0256	CbGeAlD
Sirolimus—MTOR—lung—systemic scleroderma	0.00142	0.025	CbGeAlD
Sirolimus—SLC47A1—digestive system—systemic scleroderma	0.00131	0.0231	CbGeAlD
Sirolimus—SLCO1B1—digestive system—systemic scleroderma	0.0013	0.0228	CbGeAlD
Sirolimus—FKBP1A—lung—systemic scleroderma	0.00128	0.0225	CbGeAlD
Sirolimus—SLC47A1—tendon—systemic scleroderma	0.00125	0.022	CbGeAlD
Sirolimus—SLC47A1—lung—systemic scleroderma	0.0011	0.0193	CbGeAlD
Sirolimus—FKBP1A—Spinal Cord Injury—RHOB—systemic scleroderma	0.00102	0.00929	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of mRNA—TNFSF13—systemic scleroderma	0.00102	0.00928	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00101	0.00916	CbGpPWpGaD
Sirolimus—ABCB1—blood vessel—systemic scleroderma	0.000954	0.0168	CbGeAlD
Sirolimus—EIF4E—Interferon Signaling—IRF5—systemic scleroderma	0.000934	0.00851	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—COL1A2—systemic scleroderma	0.000905	0.00824	CbGpPWpGaD
Sirolimus—MTOR—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.000903	0.00822	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—IRF8—systemic scleroderma	0.000893	0.00813	CbGpPWpGaD
Sirolimus—FGF2—Neural Crest Differentiation—RHOB—systemic scleroderma	0.000875	0.00797	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of RNA—TNFSF13—systemic scleroderma	0.000872	0.00794	CbGpPWpGaD
Sirolimus—FGF2—Angiogenesis—NOS3—systemic scleroderma	0.000859	0.00783	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—CD247—systemic scleroderma	0.000843	0.00768	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—CSK—systemic scleroderma	0.000812	0.00739	CbGpPWpGaD
Sirolimus—MTOR—Interferon type I signaling pathways—STAT4—systemic scleroderma	0.000808	0.00736	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—CSK—systemic scleroderma	0.000791	0.0072	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—CD247—systemic scleroderma	0.000763	0.00695	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000762	0.00694	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.000752	0.00685	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—STAT4—systemic scleroderma	0.000742	0.00676	CbGpPWpGaD
Sirolimus—FKBP1A—ALK1 signaling events—TGFB1—systemic scleroderma	0.000703	0.00641	CbGpPWpGaD
Sirolimus—FGF2—Angiogenesis—MMP9—systemic scleroderma	0.000689	0.00628	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.000685	0.00624	CbGpPWpGaD
Sirolimus—CYP3A5—digestive system—systemic scleroderma	0.000665	0.0117	CbGeAlD
Sirolimus—FGF2—Syndecan interactions—TGFB1—systemic scleroderma	0.000657	0.00599	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000644	0.00587	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000624	0.00568	CbGpPWpGaD
Sirolimus—EIF4E—Leptin signaling pathway—NOS3—systemic scleroderma	0.000621	0.00566	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000608	0.00554	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000596	0.00543	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000596	0.00543	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—systemic scleroderma	0.000596	0.00543	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—CSK—systemic scleroderma	0.000587	0.00534	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000584	0.00532	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—CTLA4—systemic scleroderma	0.000578	0.00527	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000564	0.00514	CbGpPWpGaD
Sirolimus—MTOR—VEGFR2 mediated vascular permeability—NOS3—systemic scleroderma	0.000564	0.00513	CbGpPWpGaD
Sirolimus—EIF4E—Interferon Signaling—HLA-DQB1—systemic scleroderma	0.000557	0.00508	CbGpPWpGaD
Sirolimus—CYP3A5—lung—systemic scleroderma	0.000556	0.00979	CbGeAlD
Sirolimus—FGF2—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	0.000548	0.00499	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—FBN1—systemic scleroderma	0.000547	0.00498	CbGpPWpGaD
Sirolimus—FGF2—Glypican 1 network—TGFB1—systemic scleroderma	0.000533	0.00485	CbGpPWpGaD
Sirolimus—EIF4E—Leptin signaling pathway—IL1B—systemic scleroderma	0.000529	0.00482	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000518	0.00472	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IL1A—systemic scleroderma	0.000517	0.00471	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.00051	0.00464	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—CSK—systemic scleroderma	0.000504	0.00459	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.0005	0.00455	CbGpPWpGaD
Sirolimus—CYP3A4—digestive system—systemic scleroderma	0.000499	0.0088	CbGeAlD
Sirolimus—MTOR—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.000484	0.00441	CbGpPWpGaD
Sirolimus—EIF4E—Validated targets of C-MYC transcriptional activation—MMP9—systemic scleroderma	0.000478	0.00436	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000478	0.00435	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—systemic scleroderma	0.000476	0.00434	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—BLK—systemic scleroderma	0.00041	0.00373	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000405	0.00369	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—systemic scleroderma	0.000404	0.00368	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000396	0.00361	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000392	0.00357	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000384	0.0035	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000383	0.00348	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000383	0.00348	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—CSK—systemic scleroderma	0.000374	0.00341	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000372	0.00339	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000371	0.00338	CbGpPWpGaD
Sirolimus—FGF2—Non-integrin membrane-ECM interactions—TGFB1—systemic scleroderma	0.000363	0.00331	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—CCL2—systemic scleroderma	0.000356	0.00324	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000353	0.00322	CbGpPWpGaD
Sirolimus—ABCB1—digestive system—systemic scleroderma	0.000353	0.00623	CbGeAlD
Sirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000353	0.00321	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000347	0.00316	CbGpPWpGaD
Sirolimus—MTOR—IFN-gamma pathway—IL1B—systemic scleroderma	0.00034	0.0031	CbGpPWpGaD
Sirolimus—FGF2—Differentiation Pathway—TGFB1—systemic scleroderma	0.000326	0.00297	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000322	0.00294	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000319	0.00291	CbGpPWpGaD
Sirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—systemic scleroderma	0.000318	0.0029	CbGpPWpGaD
Sirolimus—FGF2—Endochondral Ossification—MMP9—systemic scleroderma	0.000315	0.00287	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—BLK—systemic scleroderma	0.000304	0.00277	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.000301	0.00275	CbGpPWpGaD
Sirolimus—ABCB1—lung—systemic scleroderma	0.000295	0.0052	CbGeAlD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000293	0.00267	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—SMAD7—systemic scleroderma	0.000292	0.00266	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000274	0.0025	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—TNFSF13—systemic scleroderma	0.000272	0.00248	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—IL1B—systemic scleroderma	0.00027	0.00246	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000261	0.00237	CbGpPWpGaD
Sirolimus—FGF2—Endochondral Ossification—TGFB1—systemic scleroderma	0.000259	0.00236	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—NOS3—systemic scleroderma	0.000256	0.00233	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—MMP9—systemic scleroderma	0.000254	0.00232	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—RHOB—systemic scleroderma	0.000246	0.00224	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000244	0.00222	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—ACE—systemic scleroderma	0.000228	0.00208	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000221	0.00201	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—IL1B—systemic scleroderma	0.000218	0.00199	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000217	0.00198	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TGFB1—systemic scleroderma	0.00021	0.00191	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000209	0.0019	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CSK—systemic scleroderma	0.000207	0.00189	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IRF5—systemic scleroderma	0.000204	0.00186	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000202	0.00184	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000201	0.00183	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SMAD7—systemic scleroderma	0.000199	0.00181	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IRF8—systemic scleroderma	0.000195	0.00177	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD247—systemic scleroderma	0.000195	0.00177	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ITGAM—systemic scleroderma	0.000195	0.00177	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000193	0.00176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SMAD7—systemic scleroderma	0.00019	0.00173	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CSK—systemic scleroderma	0.00019	0.00173	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000188	0.00171	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD247—systemic scleroderma	0.000186	0.00169	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ITGAM—systemic scleroderma	0.000186	0.00169	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000184	0.00168	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000183	0.00167	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—TNFAIP3—systemic scleroderma	0.000182	0.00166	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—NOS3—systemic scleroderma	0.000182	0.00166	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFBI—systemic scleroderma	0.000182	0.00166	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000182	0.00166	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—BLK—systemic scleroderma	0.00018	0.00164	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD247—systemic scleroderma	0.000178	0.00163	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP1—systemic scleroderma	0.000174	0.00159	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—TNFAIP3—systemic scleroderma	0.000174	0.00159	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000173	0.00157	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000172	0.00156	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000167	0.00152	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000167	0.00152	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—BLK—systemic scleroderma	0.000165	0.0015	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—CTGF—systemic scleroderma	0.000162	0.00147	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000155	0.00141	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL1A—systemic scleroderma	0.000153	0.00139	CbGpPWpGaD
Sirolimus—FGF2—Disease—SMAD7—systemic scleroderma	0.000151	0.00137	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CTLA4—systemic scleroderma	0.000148	0.00134	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RHOB—systemic scleroderma	0.000147	0.00134	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—MMP1—systemic scleroderma	0.000146	0.00133	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HSPG2—systemic scleroderma	0.000145	0.00132	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000143	0.0013	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CSK—systemic scleroderma	0.000141	0.00128	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CSK—systemic scleroderma	0.00014	0.00128	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000139	0.00127	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HSPG2—systemic scleroderma	0.000139	0.00126	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000138	0.00126	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFBI—systemic scleroderma	0.000138	0.00126	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD247—systemic scleroderma	0.000138	0.00126	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ITGAM—systemic scleroderma	0.000138	0.00126	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CTLA4—systemic scleroderma	0.000135	0.00123	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP2—systemic scleroderma	0.000135	0.00123	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CSK—systemic scleroderma	0.000134	0.00122	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD247—systemic scleroderma	0.000132	0.00121	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000132	0.0012	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD247—systemic scleroderma	0.000132	0.0012	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000129	0.00118	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TNFAIP3—systemic scleroderma	0.000129	0.00118	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000124	0.00113	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—BLK—systemic scleroderma	0.000123	0.00112	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HLA-DQB1—systemic scleroderma	0.000122	0.00111	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—CCL2—systemic scleroderma	0.000119	0.00108	CbGpPWpGaD
Sirolimus—Diarrhoea—Captopril—systemic scleroderma	0.000119	0.000275	CcSEcCtD
Sirolimus—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000119	0.000275	CcSEcCtD
Sirolimus—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000274	CcSEcCtD
Sirolimus—Erectile dysfunction—Prednisone—systemic scleroderma	0.000118	0.000274	CcSEcCtD
Sirolimus—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000274	CcSEcCtD
Sirolimus—Feeling abnormal—Leflunomide—systemic scleroderma	0.000118	0.000273	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000118	0.000273	CcSEcCtD
Sirolimus—Mood swings—Methotrexate—systemic scleroderma	0.000118	0.000272	CcSEcCtD
Sirolimus—Nausea—Mometasone—systemic scleroderma	0.000117	0.000272	CcSEcCtD
Sirolimus—Anorexia—Lisinopril—systemic scleroderma	0.000117	0.000271	CcSEcCtD
Sirolimus—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000117	0.000271	CcSEcCtD
Sirolimus—Weight increased—Prednisone—systemic scleroderma	0.000117	0.000271	CcSEcCtD
Sirolimus—Pain—Mycophenolic acid—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Sirolimus—Constipation—Mycophenolic acid—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Sirolimus—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Sirolimus—Weight decreased—Prednisone—systemic scleroderma	0.000116	0.000269	CcSEcCtD
Sirolimus—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000269	CcSEcCtD
Sirolimus—Hyperglycaemia—Prednisone—systemic scleroderma	0.000116	0.000268	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL1A—systemic scleroderma	0.000115	0.00105	CbGpPWpGaD
Sirolimus—Cough—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000267	CcSEcCtD
Sirolimus—FGF2—Immune System—CSK—systemic scleroderma	0.000115	0.00105	CbGpPWpGaD
Sirolimus—Hypotension—Lisinopril—systemic scleroderma	0.000115	0.000266	CcSEcCtD
Sirolimus—Dizziness—Captopril—systemic scleroderma	0.000115	0.000266	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD40LG—systemic scleroderma	0.000115	0.00105	CbGpPWpGaD
Sirolimus—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000115	0.000266	CcSEcCtD
Sirolimus—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000264	CcSEcCtD
Sirolimus—EIF4E—Metabolism of proteins—MMP2—systemic scleroderma	0.000113	0.00103	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRF5—systemic scleroderma	0.000113	0.00103	CbGpPWpGaD
Sirolimus—Body temperature increased—Leflunomide—systemic scleroderma	0.000113	0.000262	CcSEcCtD
Sirolimus—Abdominal pain—Leflunomide—systemic scleroderma	0.000113	0.000262	CcSEcCtD
Sirolimus—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000112	0.000261	CcSEcCtD
Sirolimus—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Sirolimus—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Sirolimus—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Sirolimus—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Sirolimus—Breast disorder—Methotrexate—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Sirolimus—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Sirolimus—MTOR—Disease—SMAD7—systemic scleroderma	0.000112	0.00102	CbGpPWpGaD
Sirolimus—Hypersensitivity—Azathioprine—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Sirolimus—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000111	0.00101	CbGpPWpGaD
Sirolimus—Insomnia—Lisinopril—systemic scleroderma	0.000111	0.000258	CcSEcCtD
Sirolimus—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000257	CcSEcCtD
Sirolimus—Paraesthesia—Lisinopril—systemic scleroderma	0.00011	0.000256	CcSEcCtD
Sirolimus—Vomiting—Captopril—systemic scleroderma	0.00011	0.000256	CcSEcCtD
Sirolimus—FGF2—Disease—HSPG2—systemic scleroderma	0.00011	0.001	CbGpPWpGaD
Sirolimus—Dyspnoea—Lisinopril—systemic scleroderma	0.00011	0.000254	CcSEcCtD
Sirolimus—Rash—Captopril—systemic scleroderma	0.000109	0.000254	CcSEcCtD
Sirolimus—Dermatitis—Captopril—systemic scleroderma	0.000109	0.000253	CcSEcCtD
Sirolimus—Somnolence—Lisinopril—systemic scleroderma	0.000109	0.000253	CcSEcCtD
Sirolimus—Headache—Captopril—systemic scleroderma	0.000109	0.000252	CcSEcCtD
Sirolimus—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000252	CcSEcCtD
Sirolimus—FGF2—Immune System—ITGAM—systemic scleroderma	0.000108	0.000986	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRF8—systemic scleroderma	0.000108	0.000986	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD247—systemic scleroderma	0.000108	0.000986	CbGpPWpGaD
Sirolimus—Dyspepsia—Lisinopril—systemic scleroderma	0.000108	0.000251	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000108	0.000985	CbGpPWpGaD
Sirolimus—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Sirolimus—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—RHOB—systemic scleroderma	0.000108	0.000982	CbGpPWpGaD
Sirolimus—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Sirolimus—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Sirolimus—Asthma—Methotrexate—systemic scleroderma	0.000107	0.000249	CcSEcCtD
Sirolimus—Infection—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000248	CcSEcCtD
Sirolimus—Decreased appetite—Lisinopril—systemic scleroderma	0.000107	0.000248	CcSEcCtD
Sirolimus—FGF2—Disease—CSK—systemic scleroderma	0.000106	0.000968	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000106	0.000246	CcSEcCtD
Sirolimus—Shock—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—SMAD7—systemic scleroderma	0.000106	0.000962	CbGpPWpGaD
Sirolimus—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Sirolimus—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—Hypersensitivity—Leflunomide—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—Pancreatitis—Methotrexate—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—systemic scleroderma	0.000105	0.000958	CbGpPWpGaD
Sirolimus—Constipation—Lisinopril—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—Pain—Lisinopril—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000244	CcSEcCtD
Sirolimus—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000242	CcSEcCtD
Sirolimus—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000241	CcSEcCtD
Sirolimus—Diarrhoea—Azathioprine—systemic scleroderma	0.000104	0.00024	CcSEcCtD
Sirolimus—Haemoglobin—Prednisone—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Sirolimus—Nausea—Captopril—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Sirolimus—Haemorrhage—Prednisone—systemic scleroderma	0.000103	0.000238	CcSEcCtD
Sirolimus—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000238	CcSEcCtD
Sirolimus—Asthenia—Leflunomide—systemic scleroderma	0.000103	0.000238	CcSEcCtD
Sirolimus—MTOR—Disease—TGFBI—systemic scleroderma	0.000102	0.000933	CbGpPWpGaD
Sirolimus—Hallucination—Prednisone—systemic scleroderma	0.000102	0.000237	CcSEcCtD
Sirolimus—Pancytopenia—Methotrexate—systemic scleroderma	0.000102	0.000236	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—HSPG2—systemic scleroderma	0.000102	0.000926	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TNFAIP3—systemic scleroderma	0.000101	0.000923	CbGpPWpGaD
Sirolimus—Feeling abnormal—Lisinopril—systemic scleroderma	0.000101	0.000235	CcSEcCtD
Sirolimus—FGF2—Extracellular matrix organization—MMP9—systemic scleroderma	0.000101	0.000922	CbGpPWpGaD
Sirolimus—Pruritus—Leflunomide—systemic scleroderma	0.000101	0.000234	CcSEcCtD
Sirolimus—Connective tissue disorder—Prednisone—systemic scleroderma	0.000101	0.000234	CcSEcCtD
Sirolimus—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000233	CcSEcCtD
Sirolimus—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000101	0.000233	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—CTLA4—systemic scleroderma	0.0001	0.000914	CbGpPWpGaD
Sirolimus—Dysuria—Methotrexate—systemic scleroderma	0.0001	0.000232	CcSEcCtD
Sirolimus—Neutropenia—Methotrexate—systemic scleroderma	0.0001	0.000232	CcSEcCtD
Sirolimus—Dizziness—Azathioprine—systemic scleroderma	0.0001	0.000232	CcSEcCtD
Sirolimus—FGF2—Immune System—BLK—systemic scleroderma	0.0001	0.000912	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.0001	0.000912	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD247—systemic scleroderma	9.99e-05	0.00091	CbGpPWpGaD
Sirolimus—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.97e-05	0.000231	CcSEcCtD
Sirolimus—Erectile dysfunction—Methotrexate—systemic scleroderma	9.88e-05	0.000229	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CSK—systemic scleroderma	9.82e-05	0.000895	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.81e-05	0.000227	CcSEcCtD
Sirolimus—Asthenia—Mycophenolic acid—systemic scleroderma	9.79e-05	0.000227	CcSEcCtD
Sirolimus—Diarrhoea—Leflunomide—systemic scleroderma	9.79e-05	0.000227	CcSEcCtD
Sirolimus—Insomnia—Mycophenolate mofetil—systemic scleroderma	9.74e-05	0.000226	CcSEcCtD
Sirolimus—Body temperature increased—Lisinopril—systemic scleroderma	9.72e-05	0.000225	CcSEcCtD
Sirolimus—Abdominal pain—Lisinopril—systemic scleroderma	9.72e-05	0.000225	CcSEcCtD
Sirolimus—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	9.67e-05	0.000224	CcSEcCtD
Sirolimus—Pruritus—Mycophenolic acid—systemic scleroderma	9.66e-05	0.000224	CcSEcCtD
Sirolimus—Vomiting—Azathioprine—systemic scleroderma	9.63e-05	0.000223	CcSEcCtD
Sirolimus—Pneumonia—Methotrexate—systemic scleroderma	9.62e-05	0.000223	CcSEcCtD
Sirolimus—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	9.6e-05	0.000222	CcSEcCtD
Sirolimus—Somnolence—Mycophenolate mofetil—systemic scleroderma	9.58e-05	0.000222	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—systemic scleroderma	9.57e-05	0.000222	CcSEcCtD
Sirolimus—Infestation—Methotrexate—systemic scleroderma	9.57e-05	0.000222	CcSEcCtD
Sirolimus—Rash—Azathioprine—systemic scleroderma	9.55e-05	0.000221	CcSEcCtD
Sirolimus—Dermatitis—Azathioprine—systemic scleroderma	9.54e-05	0.000221	CcSEcCtD
Sirolimus—Headache—Azathioprine—systemic scleroderma	9.49e-05	0.00022	CcSEcCtD
Sirolimus—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	9.48e-05	0.00022	CcSEcCtD
Sirolimus—Dizziness—Leflunomide—systemic scleroderma	9.46e-05	0.000219	CcSEcCtD
Sirolimus—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	9.36e-05	0.000217	CcSEcCtD
Sirolimus—Diarrhoea—Mycophenolic acid—systemic scleroderma	9.34e-05	0.000216	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—systemic scleroderma	9.33e-05	0.000216	CcSEcCtD
Sirolimus—Angiopathy—Prednisone—systemic scleroderma	9.32e-05	0.000216	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—systemic scleroderma	9.3e-05	0.000215	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	9.3e-05	0.000215	CcSEcCtD
Sirolimus—Immune system disorder—Prednisone—systemic scleroderma	9.28e-05	0.000215	CcSEcCtD
Sirolimus—Pain—Mycophenolate mofetil—systemic scleroderma	9.21e-05	0.000213	CcSEcCtD
Sirolimus—Constipation—Mycophenolate mofetil—systemic scleroderma	9.21e-05	0.000213	CcSEcCtD
Sirolimus—Sweating—Methotrexate—systemic scleroderma	9.17e-05	0.000212	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—systemic scleroderma	9.12e-05	0.000211	CcSEcCtD
Sirolimus—Vomiting—Leflunomide—systemic scleroderma	9.1e-05	0.000211	CcSEcCtD
Sirolimus—Hypersensitivity—Lisinopril—systemic scleroderma	9.06e-05	0.00021	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.05e-05	0.00021	CcSEcCtD
Sirolimus—Dizziness—Mycophenolic acid—systemic scleroderma	9.03e-05	0.000209	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—systemic scleroderma	9.02e-05	0.000209	CcSEcCtD
Sirolimus—Rash—Leflunomide—systemic scleroderma	9.02e-05	0.000209	CcSEcCtD
Sirolimus—Dermatitis—Leflunomide—systemic scleroderma	9.01e-05	0.000209	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	9.01e-05	0.00082	CbGpPWpGaD
Sirolimus—Nausea—Azathioprine—systemic scleroderma	9e-05	0.000208	CcSEcCtD
Sirolimus—Headache—Leflunomide—systemic scleroderma	8.96e-05	0.000208	CcSEcCtD
Sirolimus—Malnutrition—Prednisone—systemic scleroderma	8.95e-05	0.000207	CcSEcCtD
Sirolimus—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000206	CcSEcCtD
Sirolimus—Asthenia—Lisinopril—systemic scleroderma	8.82e-05	0.000204	CcSEcCtD
Sirolimus—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.81e-05	0.000204	CcSEcCtD
Sirolimus—Pruritus—Lisinopril—systemic scleroderma	8.7e-05	0.000201	CcSEcCtD
Sirolimus—Vomiting—Mycophenolic acid—systemic scleroderma	8.68e-05	0.000201	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—systemic scleroderma	8.63e-05	0.0002	CcSEcCtD
Sirolimus—Rash—Mycophenolic acid—systemic scleroderma	8.61e-05	0.000199	CcSEcCtD
Sirolimus—Dermatitis—Mycophenolic acid—systemic scleroderma	8.6e-05	0.000199	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—systemic scleroderma	8.59e-05	0.000199	CcSEcCtD
Sirolimus—Headache—Mycophenolic acid—systemic scleroderma	8.55e-05	0.000198	CcSEcCtD
Sirolimus—MTOR—Immune System—CSK—systemic scleroderma	8.54e-05	0.000778	CbGpPWpGaD
Sirolimus—Pharyngitis—Methotrexate—systemic scleroderma	8.52e-05	0.000197	CcSEcCtD
Sirolimus—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	8.51e-05	0.000197	CcSEcCtD
Sirolimus—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.51e-05	0.000197	CcSEcCtD
Sirolimus—Nausea—Leflunomide—systemic scleroderma	8.5e-05	0.000197	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—systemic scleroderma	8.48e-05	0.000196	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—systemic scleroderma	8.42e-05	0.000195	CcSEcCtD
Sirolimus—Diarrhoea—Lisinopril—systemic scleroderma	8.41e-05	0.000195	CcSEcCtD
Sirolimus—MTOR—Immune System—IRF5—systemic scleroderma	8.4e-05	0.000766	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—TGFB1—systemic scleroderma	8.34e-05	0.00076	CbGpPWpGaD
Sirolimus—Ill-defined disorder—Prednisone—systemic scleroderma	8.3e-05	0.000192	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—systemic scleroderma	8.28e-05	0.000192	CcSEcCtD
Sirolimus—Anaemia—Prednisone—systemic scleroderma	8.27e-05	0.000192	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	8.26e-05	0.000753	CbGpPWpGaD
Sirolimus—Agitation—Prednisone—systemic scleroderma	8.22e-05	0.00019	CcSEcCtD
Sirolimus—FGF2—Immune System—CTLA4—systemic scleroderma	8.2e-05	0.000747	CbGpPWpGaD
Sirolimus—Angioedema—Prednisone—systemic scleroderma	8.17e-05	0.000189	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—RHOB—systemic scleroderma	8.17e-05	0.000744	CbGpPWpGaD
Sirolimus—MTOR—Disease—HSPG2—systemic scleroderma	8.17e-05	0.000744	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP2—systemic scleroderma	8.16e-05	0.000743	CbGpPWpGaD
Sirolimus—Dizziness—Lisinopril—systemic scleroderma	8.13e-05	0.000188	CcSEcCtD
Sirolimus—Nausea—Mycophenolic acid—systemic scleroderma	8.11e-05	0.000188	CcSEcCtD
Sirolimus—Malaise—Prednisone—systemic scleroderma	8.07e-05	0.000187	CcSEcCtD
Sirolimus—MTOR—Immune System—CD247—systemic scleroderma	8.03e-05	0.000732	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ITGAM—systemic scleroderma	8.03e-05	0.000732	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRF8—systemic scleroderma	8.03e-05	0.000732	CbGpPWpGaD
Sirolimus—Syncope—Prednisone—systemic scleroderma	8.02e-05	0.000186	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—systemic scleroderma	8.01e-05	0.000186	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—systemic scleroderma	7.97e-05	0.000185	CcSEcCtD
Sirolimus—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.94e-05	0.000184	CcSEcCtD
Sirolimus—MTOR—Disease—CSK—systemic scleroderma	7.89e-05	0.000718	CbGpPWpGaD
Sirolimus—Loss of consciousness—Prednisone—systemic scleroderma	7.86e-05	0.000182	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—SMAD7—systemic scleroderma	7.84e-05	0.000714	CbGpPWpGaD
Sirolimus—Vomiting—Lisinopril—systemic scleroderma	7.82e-05	0.000181	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—systemic scleroderma	7.8e-05	0.000711	CbGpPWpGaD
Sirolimus—Angiopathy—Methotrexate—systemic scleroderma	7.79e-05	0.000181	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—systemic scleroderma	7.76e-05	0.00018	CcSEcCtD
Sirolimus—Rash—Lisinopril—systemic scleroderma	7.75e-05	0.00018	CcSEcCtD
Sirolimus—Dermatitis—Lisinopril—systemic scleroderma	7.74e-05	0.000179	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—systemic scleroderma	7.74e-05	0.000179	CcSEcCtD
Sirolimus—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.73e-05	0.000179	CcSEcCtD
Sirolimus—Hypertension—Prednisone—systemic scleroderma	7.72e-05	0.000179	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—HSPG2—systemic scleroderma	7.71e-05	0.000702	CbGpPWpGaD
Sirolimus—Chills—Methotrexate—systemic scleroderma	7.71e-05	0.000179	CcSEcCtD
Sirolimus—Headache—Lisinopril—systemic scleroderma	7.7e-05	0.000178	CcSEcCtD
Sirolimus—Pruritus—Mycophenolate mofetil—systemic scleroderma	7.62e-05	0.000177	CcSEcCtD
Sirolimus—Myalgia—Prednisone—systemic scleroderma	7.62e-05	0.000176	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—systemic scleroderma	7.62e-05	0.000176	CcSEcCtD
Sirolimus—Anxiety—Prednisone—systemic scleroderma	7.59e-05	0.000176	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.56e-05	0.000175	CcSEcCtD
Sirolimus—Discomfort—Prednisone—systemic scleroderma	7.52e-05	0.000174	CcSEcCtD
Sirolimus—MTOR—Immune System—TNFAIP3—systemic scleroderma	7.52e-05	0.000685	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EDN1—systemic scleroderma	7.51e-05	0.000684	CbGpPWpGaD
Sirolimus—Malnutrition—Methotrexate—systemic scleroderma	7.48e-05	0.000173	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—CSK—systemic scleroderma	7.44e-05	0.000678	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BLK—systemic scleroderma	7.43e-05	0.000677	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD247—systemic scleroderma	7.42e-05	0.000676	CbGpPWpGaD
Sirolimus—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000171	CcSEcCtD
Sirolimus—Nausea—Lisinopril—systemic scleroderma	7.3e-05	0.000169	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—systemic scleroderma	7.3e-05	0.000169	CcSEcCtD
Sirolimus—Oedema—Prednisone—systemic scleroderma	7.3e-05	0.000169	CcSEcCtD
Sirolimus—Infection—Prednisone—systemic scleroderma	7.25e-05	0.000168	CcSEcCtD
Sirolimus—Back pain—Methotrexate—systemic scleroderma	7.23e-05	0.000168	CcSEcCtD
Sirolimus—Shock—Prednisone—systemic scleroderma	7.18e-05	0.000166	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—systemic scleroderma	7.16e-05	0.000166	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—systemic scleroderma	7.13e-05	0.000165	CcSEcCtD
Sirolimus—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.12e-05	0.000165	CcSEcCtD
Sirolimus—Skin disorder—Prednisone—systemic scleroderma	7.09e-05	0.000164	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisone—systemic scleroderma	7.06e-05	0.000164	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	7e-05	0.000638	CbGpPWpGaD
Sirolimus—Anorexia—Prednisone—systemic scleroderma	6.96e-05	0.000161	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—systemic scleroderma	6.94e-05	0.000161	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—systemic scleroderma	6.91e-05	0.00016	CcSEcCtD
Sirolimus—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000159	CcSEcCtD
Sirolimus—Rash—Mycophenolate mofetil—systemic scleroderma	6.79e-05	0.000157	CcSEcCtD
Sirolimus—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.78e-05	0.000157	CcSEcCtD
Sirolimus—FGF2—Immune System—HLA-DQB1—systemic scleroderma	6.75e-05	0.000615	CbGpPWpGaD
Sirolimus—Headache—Mycophenolate mofetil—systemic scleroderma	6.75e-05	0.000156	CcSEcCtD
Sirolimus—Malaise—Methotrexate—systemic scleroderma	6.74e-05	0.000156	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—systemic scleroderma	6.69e-05	0.000155	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.65e-05	0.000154	CcSEcCtD
Sirolimus—Insomnia—Prednisone—systemic scleroderma	6.6e-05	0.000153	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—systemic scleroderma	6.56e-05	0.000152	CcSEcCtD
Sirolimus—Cough—Methotrexate—systemic scleroderma	6.52e-05	0.000151	CcSEcCtD
Sirolimus—Dyspepsia—Prednisone—systemic scleroderma	6.43e-05	0.000149	CcSEcCtD
Sirolimus—FGF2—Immune System—IL1A—systemic scleroderma	6.42e-05	0.000584	CbGpPWpGaD
Sirolimus—Nausea—Mycophenolate mofetil—systemic scleroderma	6.4e-05	0.000148	CcSEcCtD
Sirolimus—FGF2—Immune System—CD40LG—systemic scleroderma	6.38e-05	0.000581	CbGpPWpGaD
Sirolimus—Chest pain—Methotrexate—systemic scleroderma	6.36e-05	0.000147	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—systemic scleroderma	6.36e-05	0.000147	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—systemic scleroderma	6.36e-05	0.000147	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—systemic scleroderma	6.35e-05	0.000147	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.32e-05	0.000146	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—systemic scleroderma	6.29e-05	0.000146	CcSEcCtD
Sirolimus—Constipation—Prednisone—systemic scleroderma	6.24e-05	0.000145	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—systemic scleroderma	6.15e-05	0.000143	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—MMP9—systemic scleroderma	6.13e-05	0.000559	CbGpPWpGaD
Sirolimus—Anaphylactic shock—Methotrexate—systemic scleroderma	6.1e-05	0.000141	CcSEcCtD
Sirolimus—MTOR—Immune System—CTLA4—systemic scleroderma	6.09e-05	0.000554	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RHOB—systemic scleroderma	6.06e-05	0.000552	CbGpPWpGaD
Sirolimus—Infection—Methotrexate—systemic scleroderma	6.06e-05	0.00014	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL1B—systemic scleroderma	6.02e-05	0.000548	CbGpPWpGaD
Sirolimus—Feeling abnormal—Prednisone—systemic scleroderma	6.02e-05	0.000139	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—systemic scleroderma	5.98e-05	0.000139	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—systemic scleroderma	5.97e-05	0.000138	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—systemic scleroderma	5.97e-05	0.000138	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—systemic scleroderma	5.93e-05	0.000137	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—systemic scleroderma	5.9e-05	0.000137	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	5.88e-05	0.000536	CbGpPWpGaD
Sirolimus—Anorexia—Methotrexate—systemic scleroderma	5.82e-05	0.000135	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—systemic scleroderma	5.77e-05	0.000134	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—systemic scleroderma	5.77e-05	0.000134	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—HSPG2—systemic scleroderma	5.72e-05	0.000521	CbGpPWpGaD
Sirolimus—Hypotension—Methotrexate—systemic scleroderma	5.7e-05	0.000132	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.56e-05	0.000129	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CSK—systemic scleroderma	5.52e-05	0.000503	CbGpPWpGaD
Sirolimus—Insomnia—Methotrexate—systemic scleroderma	5.52e-05	0.000128	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—EDN1—systemic scleroderma	5.51e-05	0.000501	CbGpPWpGaD
Sirolimus—Paraesthesia—Methotrexate—systemic scleroderma	5.48e-05	0.000127	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—systemic scleroderma	5.44e-05	0.000126	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—systemic scleroderma	5.42e-05	0.000126	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—HSPG2—systemic scleroderma	5.4e-05	0.000492	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisone—systemic scleroderma	5.38e-05	0.000125	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—systemic scleroderma	5.37e-05	0.000124	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—systemic scleroderma	5.3e-05	0.000123	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.27e-05	0.000122	CcSEcCtD
Sirolimus—Asthenia—Prednisone—systemic scleroderma	5.24e-05	0.000121	CcSEcCtD
Sirolimus—Pain—Methotrexate—systemic scleroderma	5.22e-05	0.000121	CcSEcCtD
Sirolimus—Pruritus—Prednisone—systemic scleroderma	5.17e-05	0.00012	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCL2—systemic scleroderma	5.13e-05	0.000467	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—systemic scleroderma	5.05e-05	0.00046	CbGpPWpGaD
Sirolimus—Feeling abnormal—Methotrexate—systemic scleroderma	5.03e-05	0.000116	CcSEcCtD
Sirolimus—MTOR—Immune System—HLA-DQB1—systemic scleroderma	5.01e-05	0.000457	CbGpPWpGaD
Sirolimus—Diarrhoea—Prednisone—systemic scleroderma	5e-05	0.000116	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.99e-05	0.000116	CcSEcCtD
Sirolimus—Dizziness—Prednisone—systemic scleroderma	4.83e-05	0.000112	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—systemic scleroderma	4.82e-05	0.000112	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—systemic scleroderma	4.82e-05	0.000112	CcSEcCtD
Sirolimus—FKBP1A—Disease—NOS3—systemic scleroderma	4.79e-05	0.000436	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1A—systemic scleroderma	4.76e-05	0.000434	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—systemic scleroderma	4.73e-05	0.000431	CbGpPWpGaD
Sirolimus—Vomiting—Prednisone—systemic scleroderma	4.64e-05	0.000108	CcSEcCtD
Sirolimus—Rash—Prednisone—systemic scleroderma	4.6e-05	0.000107	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—systemic scleroderma	4.6e-05	0.000107	CcSEcCtD
Sirolimus—Headache—Prednisone—systemic scleroderma	4.57e-05	0.000106	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NOS3—systemic scleroderma	4.57e-05	0.000417	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methotrexate—systemic scleroderma	4.5e-05	0.000104	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—CTGF—systemic scleroderma	4.46e-05	0.000406	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—systemic scleroderma	4.38e-05	0.000101	CcSEcCtD
Sirolimus—Nausea—Prednisone—systemic scleroderma	4.34e-05	0.0001	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—systemic scleroderma	4.32e-05	0.0001	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—systemic scleroderma	4.17e-05	9.67e-05	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—EDN1—systemic scleroderma	4.17e-05	0.00038	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CTGF—systemic scleroderma	4.09e-05	0.000373	CbGpPWpGaD
Sirolimus—Dizziness—Methotrexate—systemic scleroderma	4.03e-05	9.35e-05	CcSEcCtD
Sirolimus—CYP3A5—Metabolism—HSPG2—systemic scleroderma	3.9e-05	0.000355	CbGpPWpGaD
Sirolimus—Vomiting—Methotrexate—systemic scleroderma	3.88e-05	8.99e-05	CcSEcCtD
Sirolimus—Rash—Methotrexate—systemic scleroderma	3.85e-05	8.91e-05	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—systemic scleroderma	3.84e-05	8.9e-05	CcSEcCtD
Sirolimus—Headache—Methotrexate—systemic scleroderma	3.82e-05	8.86e-05	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CCL2—systemic scleroderma	3.76e-05	0.000343	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—systemic scleroderma	3.67e-05	0.000334	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS3—systemic scleroderma	3.63e-05	0.000331	CbGpPWpGaD
Sirolimus—Nausea—Methotrexate—systemic scleroderma	3.62e-05	8.4e-05	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.45e-05	0.000315	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOS3—systemic scleroderma	3.35e-05	0.000306	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—systemic scleroderma	3.35e-05	0.000305	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—systemic scleroderma	3.17e-05	0.000289	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EDN1—systemic scleroderma	3.1e-05	0.000282	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—systemic scleroderma	3.02e-05	0.000275	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CTGF—systemic scleroderma	2.96e-05	0.000269	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.94e-05	0.000268	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL2—systemic scleroderma	2.85e-05	0.00026	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS3—systemic scleroderma	2.69e-05	0.000245	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—systemic scleroderma	2.69e-05	0.000245	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOS3—systemic scleroderma	2.54e-05	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—systemic scleroderma	2.48e-05	0.000226	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—systemic scleroderma	2.4e-05	0.000219	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CTGF—systemic scleroderma	2.23e-05	0.000203	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—systemic scleroderma	2.22e-05	0.000202	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL2—systemic scleroderma	2.12e-05	0.000193	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—systemic scleroderma	2.04e-05	0.000186	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NOS3—systemic scleroderma	1.94e-05	0.000177	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOS3—systemic scleroderma	1.89e-05	0.000172	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.81e-05	0.000165	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—systemic scleroderma	1.78e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NOS3—systemic scleroderma	1.78e-05	0.000162	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—systemic scleroderma	1.68e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—systemic scleroderma	1.51e-05	0.000138	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.37e-05	0.000125	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.29e-05	0.000117	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—systemic scleroderma	1.25e-05	0.000114	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NOS3—systemic scleroderma	9.71e-06	8.85e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.98e-06	5.45e-05	CbGpPWpGaD
